Fibronectin extra domain B (EDB-FN) (EDB-FN)

Fibronectin extra domain B (EDB-FN) is a specific splice variant of the extracellular matrix glycoprotein fibronectin, characterized by the inclusion of a 91-amino acid type III homology domain. It is a prominent marker of angiogenesis and tissue remodeling, being virtually absent in healthy adult tissues but highly expressed in the neovasculature and stroma of most solid tumors, as well as in atherosclerotic plaques and fibrotic lesions (Pini et al., 1998; Schliemann et al., 2009). Due to its high stability and accessibility within the extracellular matrix, EDB-FN serves as a high-quality target for the delivery of therapeutic payloads. Clinical development has focused on antibody-cytokine fusions (immunocytokines) and radioimmunotherapy, utilizing high-affinity antibodies like L19 to concentrate agents such as Interleukin-2 or Tumor Necrosis Factor at the disease site (Neri & Bicknell, 2005). This targeting strategy aims to enhance therapeutic efficacy while minimizing systemic side effects by localizing the drug action to the tumor microenvironment. EDB-FN is also being explored as a diagnostic biomarker for PET and SPECT imaging to assess tumor angiogenesis and response to therapy (Borsi et al., 2002).

Other names

ED-BEDBOncofetal fibronectinB-FNExtra domain B of fibronectin

Targeted delivery of therapeutic payloads such as cytokines, radioisotopes, or cytotoxic agents to the neovasculature and extracellular matrix of diseased tissues by binding specifically to the EDB domain.